Anchored in work undertaken at, and licensed from, Emory University and founded by four persons wth blood industry expertise associated to that institution, Cambium Medical Technologies is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular⢠a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Through a strategic partner (Zheng Yang Biomedical Technology Co LTD, Taipei, Taiwan) Cambium commercializes worldwide its novel platelets (Aurarixâ¢) in UltraGrow-Advanced⢠as a premium stem cell growth supplement. Cambium is developing Elate Ocular⢠a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved th
